{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-263647","form_type":"8-K","ticker":"VCNX","cik":"0001205922","company_name":"VACCINEX, INC.","filed_at":"2023-10-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.438312+00:00","generated_at":"2026-06-09T08:01:30.922171+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vaccinex reports pepinemab significantly reduces GFAP biomarker in Huntington's disease; presented at CTAD.","bullets":["Pepinemab reduced plasma GFAP levels in HD patients vs placebo using highly sensitive S-PLEX immunoassay.","Data from podium presentation at CTAD Conference in Boston on October 26, 2023.","Prior phase 2 HD trial showed pepinemab prevented decline in glucose uptake and slowed cognitive decline (HD-CAB).","Ongoing SIGNAL-AD trial in Alzheimer's; last patient to complete 12-month treatment expected by June 2024.","Company sees pepinemab as potential alternative or complement to anti-Aβ antibodies for Alzheimer's."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-263647","json":"https://secwatch.observer/filing/0001193125-23-263647.json","markdown":"https://secwatch.observer/filing/0001193125-23-263647.md","text":"https://secwatch.observer/filing/0001193125-23-263647.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1205922/000119312523263647/0001193125-23-263647-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1205922/000119312523263647/d550531d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T08:01:30.922171+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}